Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Betina Ip and brain illustration

Dr Betina Ip has been awarded a Dorothy Hodgkin Fellowship by the Royal Society, for her research ' Investigating the neurochemistry of human binocular perception and plasticity using advanced in vivo high field MR spectroscopy.’ The fellowship offers a recognised first step into an independent research career for outstanding post-doctoral scientists who need a flexible working pattern due to parenting or caring responsibilities.

Dr Ip’s award will support her research on neuroplasticity in the healthy and developmentally abnormal binocular visual system. Her research can inform treatments for ‘lazy eye’, the most common visual pathology in children that is associated with loss of normal binocular vision.

A better understanding on what promotes and limits plasticity in the brain is critical for treating neurodevelopmental disorders as well as for recovery from brain injury and disease. Animal studies have shown that the inhibitory neurotransmitter GABA is an essential part of experience-dependent plasticity in the developing brain. Magnetic Resonance Spectroscopy, a non-invasive brain imaging technique, is the only method that can measure GABA levels in the living human brain. By being sensitive to the minute shifts in the magnetic resonance signal of protons generated by the chemical structure of metabolites, MRS detects and quantifies their concentrations. 

Using this ‘chemical’ camera, a major goal of Betina’s research will be to take pictures of GABA concentrations in the visual cortex of participants who learn to see better using two eyes. Through this work, she aims to understand how the adult brain reorganises due to sensory experience. 

Read more on the Royal Society website.

Similar stories

Oxford researchers uncover how Parkinson's disease protein damages brain cells

A new study reveals a key mechanism by which the protein alpha-synuclein, the hallmark of Parkinson's disease, damages neurons (brain cells) by blocking a vital cellular gateway. The results of the study, published in Nature Communications, help to explain how the disease begins and highlights a potential new target for treatment.

New Lancet review calls for urgent action to tackle the growing global threat of encephalitis

The review highlights encephalitis as an urgent global health challenge and calling for faster diagnosis, improved treatments, and strengthened prevention strategies to reduce death and disability worldwide.

Two researchers from NDCN join global network to unravel the complexity of Parkinson’s disease

Two scientists from NDCN, Professor Andrew Sharott (Team leader) and Professor Laura Parkkinen (Co-Investigator) have been selected for multi-year grants to join the Collaborative Research Network (CRN) an international, multidisciplinary, multi-institutional network working to address high-priority research questions about Parkinson's disease.

Study shows that non-invasive ultrasound shows promise for treating Parkinson’s disease

Oxford researchers have shown for the first time that ultrasound could have similar effects on brain activity in Parkinson’s sufferers as implanted deep brain stimulation (DBS) electrodes. This opens the door to new treatment approaches that could avoid surgery.

Collaboration with the Nepal Public Health Foundation (NPHF) explores maternal health and epilepsy

A new study, co-led by Professor Arjune Sen and supported by Nuffield Department of Clinical Neurosciences, aims to improve understanding of the risk factors, care pathways and broader health and social impacts of epilepsy in Nepal.